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Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) inci-
dence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics
in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with
EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily
[QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%)
were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial
plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD com-
pared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and
dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue
with dacomitinib and benefit from PFS/OS improvement.
Trial registration number: NCT01774721
First draft submitted: 23 May 2019; Accepted for publication: 24 June 2019; Published online:
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EGFR-targeted therapy is a standard treatment for EGFR mutation-positive advanced non-small-cell lung cancer
(NSCLC). Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor (TKI) that is US
FDA-approved for first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon
21 L858R substitution mutations [1]. Similar to other second-generation EGFR TKIs, dacomitinib is associated
with more potent EGFR inhibition than first-generation EGFR TKIs. This relatively potent EGFR inhibition is
associated with improved clinical efficacy. In the ARCHER 1050 trial (NCT01774721), significant improvement
was observed with dacomitinib versus the first-generation EGFR TKI gefitinib in both progression-free survival
(PFS; hazard ratio [HR]: 0.59; [95% CI: 0.47–0.74]; p < 0.0001; median PFS; 14.7 vs 9.2 months) and overall
survival (OS; HR: 0.76; [95% CI: 0.58–0.99]; p = 0.044; median OS; 34.1 vs 26.8 months) [2,3]. However,
the relatively potent EGFR inhibition seen with second-generation EGFR TKIs is also associated with EGFR-
mediated toxicities. In the ARCHER 1050 trial, EGFR-mediated toxicities reported included diarrhea, paronychia,
Future Oncol. (2019) 15(24), 2795–2805 ISSN 1479-6694 279510.2217/fon-2019-0299 C© 2019 Pfizer Inc., J Corral, TS Mok, K Nakagawa,
R Rosell, KH Lee, MR Migliorino, A Pluzanski, R
Linke, Y-L Wu
Research Article Corral, Mok, Nakagawa et al.
dermatitis acneiform and stomatitis. Furthermore, in the ARCHER 1050 trial, 66% of patients in the dacomitinib
arm experienced dose reduction (DR). However, grade 4 adverse events (AEs) occurred in only 2% of dacomitinib-
treated patients in that trial, and only 10% of dacomitinib-treated patients permanently discontinued the drug
due to study drug-related AEs [2]. The overall safety profile of dacomitinib in the ARCHER 1050 trial was similar
to that seen with other EGFR TKIs [2]. Tolerability-guided DR has proven to be an effective strategy in reducing
treatment-related AEs associated with afatinib, a second-generation EGFR TKI, in a randomized Phase II study
without negatively impacting the drug’s therapeutic efficacy [4,5].
In the ARCHER 1050 trial, the starting dose of dacomitinib for all patients was 45 mg once daily (QD), with a
maximum of two dose-level reductions permitted for treatment-related toxicities. The first DR was to 30 mg QD,
while the second was to 15 mg QD. This analysis explored the effects of dacomitinib DR on safety, efficacy and
pharmacokinetics (PK) outcomes in the ARCHER 1050 trial.
Patients & methods
Trial design & patients
The ARCHER 1050 trial design and patient eligibility criteria have been published previously [2,3]. ARCHER 1050
was an open-label, multinational, multicenter and randomized Phase III trial. Eligible patients had stage IIIB/IV or
recurrent, EGFR mutation-positive NSCLC, measurable disease by Response Evaluation Criteria in Solid Tumors
version 1.1, and an Eastern Cooperative Oncology Group performance status of 0 or 1. The primary end point of
the trial was PFS as determined by blinded independent central radiologic review. Secondary end points included
OS, best overall response, duration of response, overall safety profile, patient-reported outcomes and PK. The data
cut-off date was 17 February 2017 for OS and 29 July 2016 for all other end points. The trial was conducted in
accordance with legal and regulatory requirements, as well as the general principles set forth in the International
Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of
Medical Sciences 2002) and the Declaration of Helsinki (World Medical Association 1996 and 2008). All patients
provided written informed consent before enrollment.
Treatment
Patients were randomized (1:1) to oral dacomitinib 45 mg QD in 28-day cycles or oral gefitinib 250 mg QD in
28-day cycles (dosing and schedule details for both arms have been reported previously) [2,3]. Randomization was
stratified by EGFR mutation type (exon 19 deletion vs exon 21 L858R substitution) and race (Japanese vs mainland
Chinese vs other East Asian vs non-East Asian). All patients randomized to the dacomitinib arm started with the
standard 45 mg QD dose as per protocol. Dacomitinib DRs were permitted in order to manage treatment-related
toxicity that was not controlled with optimal supportive care, or not tolerated due to symptoms or interference
with normal daily activities regardless of severity. If, in the judgment of the investigator, a patient subsequently
tolerated treatment well at a reduced dose level, the dose was permitted to be increased to the prior dose level. When
implemented, the first dacomitinib DR was always from 45 to 30 mg QD, and the second was always from 30 to
15 mg QD. If a patient could not tolerate treatment after DR to 15 mg, treatment was discontinued. For grade 3,
grade 4 or intolerable grade 2 toxicity (using Common Terminology Criteria for Adverse Events [CTCAE] v4.0),
treatment was interrupted. Upon recovery to grade 2 or baseline, and in the clinical judgment of the investigator
with the agreement of the patient, dacomitinib treatment was resumed as follows: for interruption due to grade 3 or
intolerable grade 2 toxicity, treatment was permitted to be resumed at the same or a reduced dose level; for episodes
of grade 4 toxicity, reduction to the next dose level was mandated. Per the protocol, interruptions to manage AEs
were not anticipated to extend beyond 2 weeks. However, as permitted by the protocol, following discussion of
the clinical circumstance between the investigator and sponsor, there were individual cases where patients were
permitted to resume treatment after a lapse of greater than 2 weeks.
Assessments
Patients were observed for survival status and subsequent cancer therapies for up to 48 months from the date of the
first dose. All causality AEs were measured and graded for severity according to National Cancer Institute CTCAE
(NCI-CTCAE) v4.0. Incidence reported included all patients with an AE starting or ongoing during that interval.
Skin toxicities was a compound term consisting of two clustered terms: other skin toxicity (dry skin, nail disorder,
palmar-plantar erythrodysesthesia syndrome, paronychia, skin fissures, skin ulcer or xerosis) and rash/dermatitis
acneiform (any reported preferred term within high-level term acnes plus Medical Dictionary for Regulatory
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Activities [MedDRA] preferred terms, including drug eruption, rash, rash erythematous, rash generalized, rash
maculo-papular or rash pruritic). Diarrhea was a clustered term encompassing acute prerenal failure, azotemia,
dehydration, diarrhea, blood urea nitrogen/creatinine ratio increased, electrolyte imbalance, hypovolemia and
prerenal failure. All other reported AEs were recorded by preferred terms.
Post hoc analyses
For patients with dacomitinib DRs, frequency and severity of AEs of interest (diarrhea, dermatitis acneiform,
stomatitis and paronychia) before and after DR from 45 mg QD were analyzed by NCI-CTCAE grade. Plasma
steady-state trough concentrations (Ctrough, ss) of dacomitinib were collected at day 1 of cycle 2, after at least 14 days
of consecutive dacomitinib 45 mg QD dosing. These measurements were used to compare the initial plasma
exposure in patients who remained at 45 mg QD for the duration of treatment, patients whose dose was reduced to
30 mg QD as the lowest dose and patients whose dose was reduced to 15 mg QD as the lowest dose. Kaplan–Meier
estimates were used to construct survival curves and calculate median (with 95% CIs) PFS and OS for all patients
in the dacomitinib arm, all patients in the dacomitinib arm who underwent DR (to either 30 mg QD or 15 mg
QD as lowest dose), patients in the dacomitinib arm who remained at 45 mg QD for the duration of treatment,
patients in the dacomitinib arm who dose reduced to 30 mg QD as lowest dose and patients who dose reduced to
15 mg QD as lowest dose.
Results
Patients
Among all patients starting on the 45-mg QD dose of dacomitinib (n = 227), DRs due to AEs occurred in 150
(66.1%) patients, while 77 (33.9%) patients stayed at 45 mg QD for the duration of treatment. In total 87 patients
(38.3% of all patients randomized to the dacomitinib arm) reduced to 30 mg QD as the lowest dose and 63
patients (27.8% of all patients randomized to the dacomitinib arm) further dose reduced to 15 mg QD as the
lowest dose. Median time to DR was 12.9 weeks for the 87 patients with 30 mg QD as the lowest dose received.
For the 63 patients who received 15 mg as the lowest dose, median time to the first DR (to 30 mg QD) was
8.4 weeks and median time to subsequent DR to 15 mg QD (from 30 mg QD) was 12.4 weeks. There were
no baseline clinical characteristics that were predictive of which patients received DRs. However, DRs generally
occurred more frequently in females. Additionally, median weights, as well as the lower- and upper-range bounds
for weight, were lower in patients in both DR groups than in those remaining at 45 mg QD for the duration of
treatment (Supplementary Table 1).
Treatment exposure
Among patients treated at 45 mg QD who did not experience DRs (n = 77), the median (range) total treatment
time was 36.1 (0.3–115.1) weeks, as compared with 63.7 (5.1–162.7) weeks for patients with 30 mg QD as the
lowest dose (n = 87) and 83.7 (11.9–161.7) for patients with 15 mg QD as the lowest dose (n = 63). These numbers
reflect the entire duration of dacomitinib treatment in patients who dose reduced, by lowest dose received, not
duration of treatment only at a specific dose level.
Efficacy
Median PFS was similar in all dacomitinib-treated patients (n = 227) and those with DR (n = 150): 14.7 (95% CI:
11.1–16.6) months and 16.6 (95% CI: 14.6–18.6) months, respectively (Figure 1A). Median (95% CI) PFS by the
lowest dose received was as follows: 9.1 (5.6–12.8) months for patients (n = 77) who remained on 45 mg QD and
12.9 (10.8–16.7) months for patients (n = 87) who received 30 mg QD as the lowest dose and 31.2 (16.5–35.1)
months for patients (n = 63) who received 15 mg QD as the lowest dose (Figure 1B). Median (95% CI) OS was
also similar in all dacomitinib-treated patients (n = 227) and those with DR (n = 151): 34.1 (29.5–37.7) months
and 36.7 (32.6 – not reached [NR]) months, respectively (Figure 2A). Median (95% CI) OS for each of the lowest
dose groups was as follows: 22.0 (15.6–26.4) months for patients (n = 76) who remained on 45 mg QD and 32.6
(28.8–37.7) months for patients (n = 88) who received 30 mg QD as the lowest dose and NR (34.7–NR) months
for patients (n = 63) who received 15 mg QD as the lowest dose (Figure 2B).
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Figure 1. Progression-free survival for dacomitinib in all patients, those with dose reduction and by lowest dose. (A) Kaplan–Meier
curves for estimated PFS for all patients treated with dacomitinib (blue line; n = 227) and patients who dose reduced to either 30 mg QD
or 15 mg QD as lowest dose (green line; n = 150). (B) Kaplan–Meier curves for estimated PFS for patients who remained on 45 mg QD
dacomitinib (blue line; n = 77), patients who received 30 mg QD as lowest dose (red line; n = 87) and patients who received 15 mg QD as
lowest dose (black line; n = 63). PFS was defined as the time from randomization to objective disease progression or death from any
cause, whichever occurred first. Vertical lines on the survival curves indicate censoring of data.
IRC: Independent review committee; NR: Not reached; PFS: Progression-free survival; QD: Once daily.
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Figure 2. Overall survival for dacomitinib in all patients, those with dose reduction and by lowest dose. (A) Kaplan–Meier curves for
estimated OS for all patients treated with dacomitinib (blue line; n = 227) and patients who dose reduced to either 30 mg QD or 15 mg
QD as lowest dose (green line; n = 151). (B) Kaplan–Meier curves for estimated OS for patients who remained on 45 mg QD dacomitinib
(blue line; n = 76), patients who received 30 mg QD as lowest dose (red line; n = 88), and patients who received 15 mg QD as lowest dose
(black line; n = 63). OS was defined as the time from randomization to death from any cause. Vertical lines on the survival curves indicate
censoring of data.
†n = 151 as opposed to 150 due to later cut-off date for OS (17 February 2017) than for other end points (29 July 2016).
IRC: Independent review committee; NR: Not reached; OS: Overall survival; QD: Once daily.
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Figure 3. Grade 3 adverse events with dose reduction. Shown are incidence of grade 3 AEs of interest before (dark purple bars) and
after (lighter purple bars) dose reduction in the population of all patients experiencing a dose reduction due to an AE (n = 150). There
were no grade 4 events of interest in dacomitinib-treated patients who had a dose reduction.
†One grade 5 event occurred after dose reduction and is not included in this percentage.
‡Clustered term encompassing acute prerenal failure, azotemia, dehydration, diarrhea, blood urea nitrogen/creatinine ratio increased,
electrolyte imbalance, hypovolemia and prerenal failure.
AE: Adverse event.
Safety
Among patients who dose reduced, all patients (n = 150; 100%) experienced all-causality AEs prior to DR; 37
(24.7%) patients who dose reduced did so due to a grade 3 AE. The most common AEs leading to DR were skin
toxicities (n = 94; 62.7%), dermatitis acneiform (n = 46; 30.7%), paronychia (n = 38; 25.3%) and diarrhea (n = 21;
14.0%). The most common all-grade AEs in patients who subsequently underwent DR (n = 150) were diarrhea
(n = 132; 88.0%), paronychia (n = 82; 54.7%), dermatitis acneiform (n = 76; 50.7%) and stomatitis (n = 69;
46.0%). The incidence of grade 3 AEs of interest (diarrhea, dermatitis acneiform, stomatitis and paronychia)
decreased after DR (Figure 3). Notably, incidence of grade 3 diarrhea decreased from 11.3% (n = 17) to 4.0%
(n = 6) and that of dermatitis acneiform decreased from 15.3% (n = 23) to 6.7% (n = 10). There were no grade
4 events of interest in patients who had a DR. The incidence and severity of individual AEs of interest generally
decreased after DR (Figure 4). However, incidence and severity did not decrease in all cases. For example, while the
incidences of grade 3 dermatitis acneiform and paronychia decreased after DR, the incidence of grade 2 events did
not. Incidence of grade 2 and grade 3 diarrhea (Figure 4A), and grade 2 and grade 3 stomatitis (Figure 4C) decreased
after DR irrespective of whether 30 mg QD or 15 mg QD was the lowest dose. Permanent discontinuations due
to treatment-related AEs occurred in 22 (9.7%) patients treated with dacomitinib.
Pharmacokinetic analyses
A total of 177 patients had available Ctrough,ss data at cycle 2, day 1. Patients who received the 45 mg QD
dacomitinib dose without any DR (n = 63) tended to have lower initial plasma dacomitinib exposure, as measured
by dacomitinib Ctrough,ss at cycle 2, day 1 than those who dose reduced to either 30 mg QD (n = 67) or 15 mg
QD (n = 47) (Figure 5). Geometric mean (geometric coefficient of variation; gCV%) of Ctrough,ss at cycle 2, day 1
was 59.1 ng/ml (35%) for patients without any DR, 67.7 ng/ml (38%) for patients with 30 mg QD as the lowest
dose, and 67.6 ng/ml (61%) for patients with 15 mg as the lowest dose, respectively.
Discussion
The ARCHER 1050 trial showed significant improvement in PFS and OS for dacomitinib versus gefitinib, and in
the 66.1% (n = 150) patients who had dose adjustments the efficacy was maintained [2,3]. Toxicity management
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Figure 4. Safety by the lowest dacomitinib dose. Shown on the left side of each panel (A–D) are patients in the as-treated population
(n = 227) who stayed on the 45 mg QD dacomitinib dose (dark purple bars; n = 77), in the middle are patients (before and after dose
reduction) who received a lowest dose of 30 mg QD (lighter purple bars; n = 87), and on the right are patients (before and after dose
reduction first to 30 mg QD, then to 15 mg QD) who received a lowest dose of 15 mg QD (lightest purple bars; n = 63).
†Includes one grade 4 event in a patient who did not have a dose reduction.
‡Clustered term encompassing acute prerenal failure, azotemia, dehydration, diarrhea, blood urea nitrogen/creatinine ratio increased,
electrolyte imbalance, hypovolemia and prerenal failure.
DR: Dose reduction; QD: Once daily.
is a challenge across the entire class of EGFR TKIs, with the majority of drug-related AEs mediated by the
inhibition of epithelial EGFR expression [6,7]. The most commonly reported AEs with dacomitinib treatment
(including diarrhea, dermatitis acneiform, stomatitis and paronychia) both in the ARCHER 1050 trial [2], as
well as previous dacomitinib trials [8–10], are associated with this mechanism. With regard to second-generation
TKIs, skin and gastrointestinal toxicities related to this mechanism are the major reasons for dose modification
and discontinuation [2,11]. Permanent discontinuation due to treatment-related AEs occurred in 9.7% (n = 22)
of patients treated with dacomitinib in the ARCHER 1050 trial and in 6.3% (n = 15) of patients treated with
afatinib in the LUX-Lung 6 trial [4]. The DR rates for these treatment groups, meanwhile, were 66.1% (n = 150)
and 28.0% (n = 67) in ARCHER 1050 and LUX-Lung 6, respectively [4]. However, this safety profile comparison
should be made with caution for several reasons. First, LUX-Lung 6, in contrast to ARCHER 1050, was conducted
exclusively in an Asian patient population. Additionally, cross-trial comparison is difficult in general due to potential
differences in a number of other variables (e.g., trial design details, age of patients, disease stage and disease subtype).
The current analysis revealed that dose modifications helped to manage AEs without the need for permanent
discontinuation in the majority of patients, while maintaining efficacy. Additionally, dacomitinib DRs decreased
the incidence and severity of all-causality AEs. Notably, the incidence of grade 2 and grade 3 diarrhea and stomatitis,
two AEs with higher grade incidence at the starting dose of 45 mg QD in ARCHER 1050, decreased after DR.
While the incidence of grade 3 dermatitis acneiform and paronychia also decreased after DR, the incidence of grade
2 events did not. We hypothesize that the increase seen in grade 2 dermatitis acneiform events following DR may
in part be a result of grade 3 events converting to grade 2 events. The exact reason for the observed increase in
grade 2 paronychia events following DR is unclear.
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Figure 5. Comparison of dacomitinib initial exposure between lowest dose groups after first treatment cycle. Shown is a comparison of
trough plasma concentrations on day 1 of cycle 2 in patients remaining on dacomitinib 45 mg QD (blue symbols; n = 64), dose reducing to
30 mg QD (red symbols; n = 74) as lowest dose, or dose reducing to 15 mg QD as lowest dose (black symbols; n = 47). All patients received
45 mg QD dacomitinib at the time of measurement. Boxes represent the median and interquartile range; the whiskers represent the 10th
and 90th percentiles and the dots show data points outside percentiles.
QD: Once daily.
The PK analysis showed that patients who remained at 45 mg QD tended to have the lowest initial dacomitinib
exposure, compared with those patients who had their dose reduced to 30 mg QD or 15 mg QD as the lowest
dose. These results are similar to those seen with the second-generation TKI afatinib, where, at day 22, the patient
group that would remain on the starting dose (40 mg QD) until day 43 had lower exposure than the group that
had the dose reduced (to 30 mg QD) by day 43 [4]. Also, similar to results in the present report, patients whose
dose reduced to 30 mg QD afatinib in the first 6 months of treatment had median PFS comparable with that in
patients remaining on the 40 mg QD starting dose [4]. Coupled with the fact that there are no apparent baseline
characteristics predictive of which patients will eventually have a DR, the exposure data in the current report are not
sufficient to determine whether starting on a lower dose (e.g., 30 mg QD) could be appropriate. Further studies,
potentially in conjunction with modeling and simulations based on available clinical data, are needed to assess if,
and for which patients, a lower starting dose might be prudent. In this regard, it should be noted that starting an
EGFR TKI at a lower dose is common in real-world clinical practice. One recent study with afatinib showed that
starting patients at a lower dose (31% started on less than the standard starting dose of 40 mg QD) did not result
in compromised efficacy [5].
When interpreting the PFS and OS results summarized by the lowest dose received, it is important to recognize
that comparisons across lowest dose levels of patients who dose reduced are confounded by the fact that the lowest
dose received was a study outcome, and therefore, PFS and OS results by lowest dose received were outcome driven
and not based on criteria present at randomization, as all patients received 45 mg QD as the starting dose. Further,
the time to each successive DR was not immediate. The median time to DR for the 87 patients who dose reduced
to 30 mg QD as the lowest dose received was 12.9 weeks, while for the 63 patients who subsequently dose reduced
to 15 mg as the lowest dose received, median time to the first DR (to 30 mg QD) was 8.4 weeks and median time
to the subsequent DR to 15 mg QD (from 30 mg QD) was 12.4 weeks. It is important to note that nonresponding
patients with short treatment duration were less likely to have undergone DR at all. Since all patients started on
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the 45 mg dose, and patients who eventually had their dose reduced remained on 45 mg QD for some time before
DR, no conclusions can be drawn as to the potential efficacy of starting doses of either 30 mg QD or 15 mg QD,
and direct statistical comparisons between the presented DR groups would not be informative with respect to those
starting doses. A limitation of the study is that no conclusions can be drawn concerning the potential effect of
DRs on the progression or control of brain metastases, since patients with brain metastases were excluded from
participation in ARCHER 1050.
Conclusion
In summary, we found that the incidence and severity of AEs declined following DR (e.g., grade 3 dermatitis
acneiform was reduced from 15.3 to 6.7%). However, both median PFS (14.7 and 16.6 months) and median OS
(34.1 and 36.7 months) were similar in all dacomitinib-treated patients and those with DR. Thus, tolerability-
guided dose modifications enabled patients to continue with dacomitinib treatment and benefit from improvement
in PFS and OS.
Summary points
• Dose modifications decreased the incidence and severity of treatment-related adverse events.
• Initial plasma dacomitinib exposure at 45 mg QD was generally lower in patients remaining at 45 mg QD
compared with dose-reducing patients.
• The benefit of progression-free survival (PFS) and overall survival (OS) was maintained in patients who received
dose reductions.
• Both median PFS and median OS were similar in all dacomitinib-treated patients and those with dose reduction.
• Tolerability-guided dose modifications enabled patients to manage AEs and continue with dacomitinib treatment
and benefit from improvement in PFS and OS.
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